GBS Polysaccharide-Protein Conjugates for Broad Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Group B Streptococcus (GBS) do not effectively cover emerging serotypes VI, VII, VIII, and IX, which pose a significant risk, especially in the elderly population, and existing vaccines have limited coverage against invasive strains in North America and Europe.
Innovation Solution
Development of immunogenic polysaccharide-protein conjugates comprising capsular polysaccharides from GBS serotypes VI, VII, VIII, and IX, with a sialic acid level greater than 60%, conjugated with carrier proteins like CRM197, Diphtheria toxoid, or Tetanus toxoid, to induce a broad immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing vaccines are used, then protection against traditional GBS serotypes is provided, but coverage against emerging serotypes VI, VII, VIII, and IX is insufficient
Solution Approach 1:
The vaccine composition is designed to provide universal protection against multiple GBS serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX) by including polysaccharide-protein conjugates from each serotype. This multi-functional approach allows a single vaccine to address both traditional and emerging serotypes, resolving the contradiction between maintaining protection against traditional serotypes and adding coverage for emerging ones.
2Adaptability or versatility
If polysaccharide-protein conjugates are developed for emerging serotypes, then broader immune response is induced, but vaccine complexity increases
Solution Approach 1:
The patent combines multiple polysaccharide-protein conjugates from different serotypes into a single integrated vaccine composition. By merging the protective components for serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX into one formulation, the vaccine achieves broad serotype coverage while presenting a unified, manageable product rather than multiple separate vaccines.
3Reliability
If high sialic acid level polysaccharides (>60%) are used in conjugates, then immunogenicity is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies a minimum sialic acid level threshold (>60%) as a critical parameter for ensuring enhanced immunogenicity of the polysaccharide-protein conjugates. By establishing this clear quantitative criterion, the invention provides a measurable standard for manufacturing quality control, allowing producers to monitor and maintain the necessary sialic acid content while ensuring the conjugates achieve the desired immunogenic effect.
Data Source
AI summary
The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.